Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovations in Europe, particularly through links with many institutes. research and prestigious hospitals.

Kurma Partners

Agoranov is a public Science & Tech incubator that provides mentorship, office space, funding, and consultancy services to startups. The company is based in Paris. Agoranov has supported more than 380 startups that have already created more than 7,000 direct jobs and raised €700 million from private funds. Among them Criteo (NASDAQ: CRTO), Anevia, Biophytis, Gensight and Pixium listed on Alternext, or Aldebaran, Dataiku, Doctolib, Point Vision and Ynsect. Agoranov, founded by the Universities Pierre and Marie Curie and Paris-Dauphine, Ecole Normale Supérieure, ParisTech, and INRIA, is supported by the Ministry of Research and Higher Education, the Ile de France Region, the City of Paris and the European Social Fund. Agoranov provides its 60 incubated with personalized support, a state-of-the-art acceleration program, quality accommodation in the center of Paris and a rich community of several hundred entrepreneurs.

AGORANOV

Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage. The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact its collective future. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs. It was headquartered in Paris, Ile-de-France in 1972.

Sofinnova Partners

Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments.  Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets under management.

Casdin Capital

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.

Bpifrance

Genoa Ventures invests in early-stage life sciences technology companies. They fund entrepreneurs and companies looking to change the way science gets done with new tools and technologies. Sector focus areas include research tools, molecular diagnostics, synthetic biology, and industrial biology. Genoa Ventures was founded in 2014 by Jenny Rooke and is based in San Francisco, California, United States.

Genoa Ventures

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.

Alexandria Venture Investments

Meiogenix

Meiogenix is a biotech company developing breeding technologies to unlock the unexplored genetic diversity of organisms. Meiogenix expands the natural biodiversity and helps developing new products to address global food and industrial challenges.

<div>Meiogenix is a French agriculture biotech company that partakes in chromosome editing to develop new crops. The varieties of crops, using meiotic recombination, expand the biodiversity available to farmers, which is claimed to overcome climate change and food insecurity challenges. The company&rsquo;s SpiX technology targets homologous recombination in plant genomes, which allows the re-assembly of crop traits during the breeding process. The recombination process is claimed to reduce lengthy breeding cycles from 6&ndash;13 years to 3&ndash;7 years and allows the development of entirely new complex traits.</div>

Enhancing seed and crop traits via biotechnology

Crop Biotech

Meiogenix Names Ricardo Garcia de Alba as New CEO to Drive Global Agricultural Innovation

Bayer

Announced a collaboration to advance agricultural research and development by accelerating the development of Meiogenix’s proprietary technologies related to plant breeding and genome editing applications

Companies that develop a platform to insert, edit, or delete the DNA of a plant itself using approaches such as CRISPR-Cas 9, TALENs, and Zinc Fingers. These approaches help develop plant genes or seeds with traits such as disease-resistant, enhanced-performance, or improve yield.

<div>
 
 Meiogenix is a French agriculture biotech company that partakes in chromosome editing to develop new crops. The varieties of crops, using meiotic recombination, expand the biodiversity available to farmers, which is claimed to overcome climate change and food insecurity challenges. The company&rsquo;s SpiX technology targets homologous recombination in plant genomes, which allows the re-assembly of crop traits during the breeding process. The recombination process is claimed to reduce lengthy breeding cycles from 6&ndash;13 years to 3&ndash;7 years and allows the development of entirely new complex traits.
 
 
 In 2021, Meiogenix was developing three applications: the transfer of gene edits or transgenes into a large number of commercial germplasm; the isolation of useful crop traits from low agronomic performance of wild varieties; and the generation of complex crop traits, such as flavor, drought tolerance, nitrogen, or water use. As of 2021, the company&rsquo;s product focus was on corn, tomato, rice, and soybean, with further plans to develop crop varieties in other fruits and vegetables.
 
 
 Key customers and partnerships&nbsp;
 
 
 The company partnered with the French Centre de coop&eacute;ration Internationale en Recherche Agronomique pour le D&eacute;veloppement (CIRAD) in February 2011 to research the impact of Meiogenix&rsquo;s SpiX technology on rice genomes.
 
 
 It partnered with Bayer in April 2016, providing Meiogenix&rsquo;s SpiX license for use in crop development. In February 2020, Meiogenix partnered with Bayer again to collaboratively improve its recombination technology.
 
 
 Meiogenix also partnered with Lesaffre in June 2016 to use the former&rsquo;s recombination technology to develop improved industrial yeast strains for Lesaffre&rsquo;s yeast manufacturing. 
 
</div>

<div>
 
 PLANTeDIT is a biotech company that develops agricultural solutions by using advanced genome editing tools, specifically CRISPR/Cas9 ribonucleoproteins (RNPs), to create sustainable food products. One of PLANTeDIT's key projects is the development of non-transgenic high-oleic soybeans, which are created by mutating the FAD2 gene in soybeans, resulting in increased oleic oil content.&nbsp;
 
 
 High oleic oils are valued in the food industry for their stability and shelf life, making them a suitable replacement for hydrogenated oils that contain trans fats. PLANTeDIT's high oleic soybean oil has potential applications in various food products, including packaged baked goods, cereal coatings, crackers, dried fruits, and non-dairy creamers.
 
 
 Key customers and partnerships
 
 
 In October 2017, PLANTeDIT partnered with biotech company ToolGen, Inc., to receive access to ToolGen's CRISPR platform and licenses for other gene-editing tools for the company's R&amp;D in crop improvement areas such as resilience to harsh climates, increased nutrition, and higher yield.
 
</div>

PLANTeDIT

<div>
 
 Amfora is an agricultural biotech company that uses CRISPR-Cas9 gene editing technology to make plant-based alternatives for animal protein and increase the protein content of staple food crops. The company also uses DNA markers, phenotyping tools such as single-seed near-infrared spectroscopy (NIR), and AI tools for advanced crop breeding methodologies to enhance crop genes affecting the protein, oil, and yield content in feed crops.
 
 
 Amfora is developing a family of feed and food crops, the latter of which includes soybeans wheat, and rice, and provides the suppliers of plant-based meat and dairy alternatives with their primary ingredients. The company is also involved in aquaculture feed with the development of a low-cost plant-based protein for farmed seafood.
 
 
 The company&rsquo;s patented CRISPR technology leverages gene editing to control the balance between protein and carbohydrates, thereby increasing protein in all crops. The CRISPR technology also lowers the glycemic index and starch, optimizes the amino acid profile, and enhances micronutrients in its food crops.
 
 
 In May 2024, Amfora announced it received approval from the US Department of Agriculture&rsquo;s Animal and Plant Health Inspection Service (APHIS) for its soybean, with expected commercialization by 2027.
 
 
 
 
 
 Key customers and partnerships&nbsp;
 
 
 Amfora partnered with the Australian Commonwealth Scientific and Industrial Research Organisation (CSIRO) in April 2017 and Corteva Agriscience in April 2019 to receive licenses from the two partners to develop oil and protein content in food crops.
 
 
 In March 2021, it partnered with Plastomics to use its trait delivery technology to introduce Amfora&rsquo;s gene-editing constructs into soybean germplasm. The company partnered with McClintock in July 2023 to combine its phenotyping tools with McClintock&rsquo;s AI and machine learning breeding solutions to accelerate efforts of increasing soybean productivity.
 
</div>

Amfora

<div>
 
 BioHeuris is an Argentine biotech company that combines synthetic biology with CRISPR gene editing to develop hybrid herbicide-resistant crops to reduce the use of herbicides increasing sustainability and reducing development costs and time to market.&nbsp;
 
 
 BioHeuris has two technology platforms&mdash;Heurik and Swap. Heurik is a high-throughput platform that uses directed evolution and designs of herbicide targets to identify mutations that allow herbicide resistance. Heurik can select gene variants and compare their microorganisms' efficiency and anticipate their effect on crops. Swap is a non-genetically modified organism (non-GMO) platform that combines tissue culture with gene editing techniques to precisely introduce changes and confer herbicide resistance in crops.&nbsp;
 
 
 BioHeuris&rsquo; variety of crop developments with partners include soybean, sorghum, rice, cotton, alfalfa, peanut, maize, and sunflower. The company is developing high-yielding resilient crop varieties for soybean, cotton, and alfalfa. For the rest of the crops, BioHeuris is focusing on developing herbicide and climate-resistant hybrid varieties.&nbsp;
 
 
 Key customers and partnerships&nbsp;
 
 
 BioHeuris partnered with Benson Hill in May 2018 and Gensus in May 2021 to apply the company&rsquo;s gene editing technology in developing herbicide-tolerant crops for soybeans, sorghum, and wheat for the former and cotton for the latter. It also partnered with Grupo Don Mario (GDM) in June 2021 for the development of high-yielding soybean varieties using gene editing.&nbsp;
 
 
 In February 2022, BioHeuris partnered with AgIdea to develop a single platform, the Agile Breeding platform, providing genome editing, breeding services, and double haploid tools to seed companies. 
 
</div>

BioHeuris

<div>
 
 UK-based Tropic Biosciences (Tropic) develops genetic innovation for tropical crops to increase crop yield and sustainability. Tropic uses pioneering technologies, including CRISPR gene editing, to increase crop disease and climate resistance, reduce supply chain waste, and reduce dependence on pesticides.&nbsp;
 
 
 Tropic&rsquo;s in-house gene editing platform, Gene Editing-induced Gene Silencing (GEiGS), combines gene editing precision with gene silencing (RNAi) and innovates vast gene editing possibilities in crops to improve their natural traits.
 
 
 The company&rsquo;s tropical crops offered are varieties of bananas, rice, and coffee. The bananas are developed with gene editing to be resistant to the Panama and Black Sigatoka diseases, have an extended shelf life, and reduce food waste and CO2 emissions by over 25%. Using gene silencing, Tropic makes its coffee low in caffeine and increases solubility with gene editing. The company uses gene editing for rice to make them high-yielding and disease-resistant.
 
 
 Key customers and partnerships&nbsp;
 
 
 To use its GEiGS platform for developing crop traits, crop varieties and improving livestock protein feed, Tropic Biosciences partnered with Baden Aniline and Soda Factory (BASF) in July 2020, Genus in October 2020, British Sugar in March 2023, and Corteva Agriscience in October 2023.
 
 
 Tropic Biosciences received a license of access for Pairwise&rsquo;s base editing technologies in February 2022 to accelerate breeding innovation in coffee and banana crops for the former.
 
</div>

Tropic Biosciences

Companies that develop or use biological, physical and chemical agents and techniques to provide protection and improve the quality of a seed. This includes the sale of seed coating, or seed enhancement products as methods to treat seeds.

Companies that redesign large clusters of genes and gene parts rather than modifying or engineering a single gene for improving the traits of a plant.

Companies that utilize genetic engineering tools and technologies to use existing and naturally present gene variants in a plant and the natural process of breeding such as inbreeding, and linebreeding to develop better traits for plants.

Companies that use transgenesis processes like tissue culturing to develop transgenic plants or seeds by inserting new genes into them from other plants or in certain instances other organisms like bacteria or even animals.

Companies that offer techniques such as epigenetics, RNA interference (RNAi) to temporarily block a specific gene that would trigger unwanted effect such as a disease on a plant.

Offers customization of genes and traits as required by farmers

Biotech solutions to produce crops that are sustainable and offer better traits

Uses AI/machine learning to facilitate their platform/biotech processes like gene editing

Meiogenix

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless